211 related articles for article (PubMed ID: 29497605)
41. Emerging Therapies in Metastatic Prostate Cancer.
Sonnenburg DW; Morgans AK
Curr Oncol Rep; 2018 Apr; 20(6):46. PubMed ID: 29644451
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.
Ozono S; Tsukamoto T; Naito S; Horie S; Ohashi Y; Uemura H; Yokomizo Y; Fukasawa S; Kusuoka H; Akazawa R; Saito M; Akaza H
Cancer Sci; 2018 Jun; 109(6):1920-1929. PubMed ID: 29624800
[TBL] [Abstract][Full Text] [Related]
43. Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.
Sade JP; Báez CAV; Greco M; Martínez CH; Avitia MÁÁ; Palazzo C; Toriz NH; Trujillo PIB; Bastos DA; Schutz FA; Bella S; Nogueira L; Shore ND
Med Oncol; 2018 Mar; 35(4):56. PubMed ID: 29556815
[TBL] [Abstract][Full Text] [Related]
44. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
45. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
[TBL] [Abstract][Full Text] [Related]
46. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
47. Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?
Cabarkapa S; Perera M; Sikaris K; O'Brien JS; Bolton DM; Lawrentschuk N
Prostate Int; 2018 Mar; 6(1):1-6. PubMed ID: 29556482
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
Patel A; Fong L
Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Castration-naive Metastatic Prostate Cancer.
Hamilou Z; Baciarello G; Fizazi K
Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
[TBL] [Abstract][Full Text] [Related]
50. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
Vander Ark A; Cao J; Li X
Front Oncol; 2018; 8():180. PubMed ID: 29911070
[TBL] [Abstract][Full Text] [Related]
52. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
[TBL] [Abstract][Full Text] [Related]
53. Molecular and cellular mechanisms of castration resistant prostate cancer.
Huang Y; Jiang X; Liang X; Jiang G
Oncol Lett; 2018 May; 15(5):6063-6076. PubMed ID: 29616091
[TBL] [Abstract][Full Text] [Related]
54. Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.
Poon DMC; Chan K; Lee SH; Chan TW; Sze H; Lee EKC; Lam D; Chan MFT;
Prostate Int; 2018 Mar; 6(1):24-30. PubMed ID: 29556486
[TBL] [Abstract][Full Text] [Related]
55. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
56. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
[TBL] [Abstract][Full Text] [Related]
58. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
[TBL] [Abstract][Full Text] [Related]
59. Local treatment for metastatic prostate cancer: A systematic review.
Tilki D; Pompe RS; Bandini M; Marchioni M; Kretschmer A; Tian Z; Karakiewicz PI; Evans CP
Int J Urol; 2018 May; 25(5):390-403. PubMed ID: 29572963
[TBL] [Abstract][Full Text] [Related]
60. Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate.
Murata H; Koyama K; Takezawa Y; Nishigaki Y
Mol Clin Oncol; 2018 Apr; 8(4):587-591. PubMed ID: 29541468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]